-

11:31:09 PM

GRAY Stock News

GRAY -

03/20/23 1:22 PM

Nasdaq : GRAY

low float

Graybug Announces Name and Trading Symbol Change

Graybug Vision, Inc. (Nasdaq: GRAY) (Graybug) today announced that it has changed its name to CalciMedica, Inc. (the Company), which will become effective at 4:02 pm ET. In connection with the name change, the Company has changed its

RHEA-AI

neutral

11/21/22 6:52 PM

Nasdaq : GRAY

acquisitionlow float

Graybug and CalciMedica Enter into Definitive Merger Agreement

– Merger to create Nasdaq-listed, clinical-stage biopharmaceutical company focused on advancing CalciMedica’s pipeline of first-in-class product candidates for life-threatening inflammatory diseases – Combined company is expected to be funded with cash and cash equivalents of approximately $35

RHEA-AI

positive

11/10/22 4:58 PM

Nasdaq : GRAY

earningslow float

Graybug Vision Reports Financial Results for the Three and Nine Months Ended September 30, 2022

Graybug Vision, Inc. (Nasdaq: GRAY) (“Graybug” or the “Company”), a clinical-stage biopharmaceutical company focused historically on developing transformative medicines for ocular diseases, today reported financial results for the three and

RHEA-AI

very negative

08/11/22 7:30 AM

Nasdaq : GRAY

earningslow float

Graybug Vision Reports Financial Results for the Three and Six Months Ended June 30, 2022, and Recent Corporate Developments

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported

RHEA-AI

neutral

07/06/22 7:15 AM

Nasdaq : GRAY

conferenceslow float

Graybug to Present at the 2022 OIS Retina Innovation Summit

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming Ophthalmology Innovation Source

RHEA-AI

neutral

06/28/22 7:15 AM

Nasdaq : GRAY

low float

Graybug Announces Review of Strategic Alternatives

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that its Board of Directors will conduct a comprehensive review of

RHEA-AI

neutral

05/19/22 7:30 AM

Nasdaq : GRAY

conferencesclinical triallow float

Graybug to Present Clinical Development Plan Update for GB-102 at the 2022 Clinical Trials at the Summit Meeting

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced that Parisa Zamiri, MD, PhD, Chief Medical Officer of Graybug Vision,

RHEA-AI

neutral

05/10/22 4:05 PM

Nasdaq : GRAY

earningslow float

Graybug Vision Reports First Quarter 2022 Financial Results and Recent Corporate Developments

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for ocular diseases, today provided an update on recent corporate developments and anticipated milestones, and reported

RHEA-AI

neutral

04/27/22 7:30 AM

Nasdaq : GRAY

conferencesclinical triallow float

Graybug to Present Preclinical Data for GB-401 in Primary Open-Angle Glaucoma at the 2022 ARVO Annual Meeting

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a poster presentation of preclinical data for GB-401 in primary

RHEA-AI

neutral

04/18/22 7:30 AM

Nasdaq : GRAY

conferenceslow float

Graybug to Present at the 2022 ASCRS Annual Meeting

Graybug Vision, Inc. (Nasdaq: GRAY), a clinical-stage biopharmaceutical company focused on developing transformative medicines for the treatment of ocular diseases, today announced a platform presentation at the upcoming American Society of Cataract

RHEA-AI

neutral